Weight-loss drugs can be broadly categorized into prescription medications and over-the-counter supplements. Each category has distinct characteristics and regulations governing its usage.
Wegovy and Ozempic
The Danish pharmaceutical giant Novo Nordisk, known as a global leader in diabetes treatments, utilizes the drug semaglutide in two of its key treatments: Wegovy for obesity and Ozempic for Type 2 diabetes.
Wegovy obtained approval in the United States in 2021 and is currently available for purchase in Denmark, Norway, Britain, and Switzerland. Novo Nordisk aims to secure certification in France in the coming year.
On the other hand, Ozempic received authorization in the US back in 2017. Recent supply shortages in the US stemmed from a surge in demand, largely driven by individuals seeking weight loss, often influenced by positive endorsements from celebrities or influencers across social media platforms.
Projections indicate substantial sales for Wegovy and Ozempic in the United States alone, estimated at $8.1 billion and $2.1 billion, respectively, by 2031, as per a March report from GlobalData.
Mounjaro and Zepbound from Eli Lilly
Eli Lilly’s medication tirzepatide, known as Mounjaro for individuals dealing with Type 2 diabetes, received approval from US health authorities last year. Additionally, it has been prescribed off-label, indicating its use for purposes not explicitly approved, particularly for aiding in weight loss.
Recently, tirzepatide obtained US approval specifically for the treatment of obesity, to be marketed under the name Zepbound, granted on November 8.
Zepbound is recommended for individuals classified as obese or overweight, especially those with underlying conditions such as Type 2 diabetes, elevated cholesterol levels, or high blood pressure.
Comments
Post a Comment